Precision medicine service for liver cancer
From 2006, top tier liver cancer clinical research with highest-quality of data worldwide via collaborative research with top class research institutes(Ajou University Hospital, Samsung Medicial center, and Asan medical center etc.). It's leading to world-class research outputs and commercialized products.
The precision medicine service provides one-stop test that includes sample assay and genomic data analysis to facilitate
- determination of cancer treatment on surgery
- determination of therapeutic interventions
- selection of alternative off-label interventions to serve all patients suffering from liver cancer.
The service is expected to launch in the first half of 2020.
<OncoHePaTest® Scientific Publication> Cancer Science 101(6): 1521-1528
<New Health Technology> The Ministry of Health and Welfare: 2010-83
<OncoHePaTest® KIT Certificate> KFDA Notice 13-511, Domestic & Worldwide patents WO2010120143A2, WO2010120143A3
Successful validation of OncoHePaTest® in Japanese HCV-HCC patients
- predict 5-year survival / 2-year recurrence in HCV derived HCC patients (Japanese)
Successful validation of OncoHePaTest® in small solitary HCC patients, Ann Surg Treat Res. 2018 Dec;95(6):303-311
- predict 5-year survival/recurrence in small solitary HCC patients
Biomarker pipelines for cancer drug repositioning
|Pipeline||Drug Development||Phase I||Phase II||Phase III|
|Biomarker Development||Single center Validation||Multi-center validation (Global)|
|Liver Fibrosis||Prognosis of progressiveness|
|PREDICTIVE||HCC Nexavar® （ORR）|
|HCC Nexavar® (DCR)|
|TNBC Doxorubicin + Cyclophosphamide|
|HNSCC First line palliative therapy|
|SCLC Keytruda + Taxol|
|PSC IMFINZI + Tremelimumab (Immune therapy)|